Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.”
Results of a phase I/II study showed the feasibility and activity of the all-oral regimen of ixazomib-melphalan-prednisone (IMP) induction treatment followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
“This study demonstrates the feasibility, tolerability, and antimyeloma activity of the all-oral IMP induction regimen followed by long-term maintenance with single-agent oral ixazomib in elderly, transplant-ineligible patients with newly-diagnosed multiple myeloma,” Jesus F. San-Miguel, MD, PhD, of Clinica Universidad de Navarra, Pamplona, Spain, and colleagues wrote in Haematologica.
“Oral dosing, coupled with a favorable safety profile at the recommended phase II dose, make ixazomib particularly suitable for long-term continuous therapy and may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI [proteasome inhibitor] in this setting.”
The phase I portion of the study enrolled 61 patients into four arms to investigate weekly or twice-weekly ixazomib combined with melphalan-prednisone. Patients in Arms A and B were treated with 13 or fewer 28-day cycles of the drug, and patients in Arms C and D received 9 or fewer 42-day cycles.
In phase I, about 1 in 4 patients reported dose-limiting toxicities during the first cycle, including grade 3 and/or grade 4 neutropenia in 6 patients, and thrombocytopenia in 4 patients. The recommended phase II dose was weekly ixazomib at 4.0 mg. In phase II, an expansion cohort was enrolled at the recommended dose.
At the final analysis, 4 patients remained on treatment. Reasons for discontinuation included disease progression, trial withdrawal, and completion of protocol-specific treatment.
With a median follow-up of 43.6 months for overall survival (OS), patients received a median of 16 cycles of ixazomib. Thirty-six patients went on to receive maintenance ixazomib, for a median of 12 cycles, the maximum duration of ixazomib treatment was 58 months.
About half of patients (48%) had a complete response (CR) or very good partial response (PR), 28% of these patients had a CR or better, and 48% of these occurred at the recommended phase II dose of weekly ixazomib 4.0 mg.
The overall response rate was 66%. The median times to very good PR and CR was 3.7 months and 11.6 months, respectively. One high-risk patient achieved CR and 3 high-risk patients achieved PR.
Maintenance therapy showed a deepening of responses in about one-third of patients, with 2 patients moving from CR to stringent CR, 5 patients moving from very good PR to stringent CR, and 3 patients moving from very good PR to CR.
“The number of patients who continued on long-term single-agent ixazomib maintenance therapy further emphasizes the tolerability of this regimen,” the researchers wrote.
The most common adverse events (AEs) of grade 3 or worse were thrombocytopenia, neutropenia, lymphopenia, leukopenia, anemia, and diarrhea. Hematologic toxicities occurred less frequently at the recommended phase II dose. There were three on-study deaths but none were considered to be treatment-related.
“Importantly, the continued clinical benefit demonstrated with weekly single-agent ixazomib maintenance therapy was complemented by a favorable tolerability profile,” the researchers wrote. “The majority of AEs were observed during the induction period, only 6% of patients discontinued ixazomib maintenance because of AEs, and no on-study deaths occurred during maintenance.”
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.